about
The role of regulatory T cells in the modulation of anti-tumor immune responsePotential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients.Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinomaDifferential Immunometabolic Phenotype in Th1 and Th2 Dominant Mouse Strains in Response to High-Fat Feeding.ST2 deletion enhances innate and acquired immunity to murine mammary carcinomaDeletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma.IL-33/ST2 axis in inflammation and immunopathology.The frog skin host-defense peptide frenatin 2.1S enhances recruitment, activation and tumoricidal capacity of NK cells.Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic isletsIn vivo administration of the frog skin peptide frenatin 2.1S induces immunostimulatory phenotypes of mouse mononuclear cells.IL-33/ST2 axis in innate and acquired immunity to tumors.Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets.Oxidative stress accelerates spontaneous apoptosis of B-chronic lymphocytic leukemia lymphocytes.An analog of the host-defense peptide hymenochirin-1B with potent broad-spectrum activity against multidrug-resistant bacteria and immunomodulatory properties.The Potential of Frog Skin-Derived Peptides for Development into Therapeutically-Valuable Immunomodulatory Agents.Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance?Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia.Attenuation of NK cells facilitates mammary tumor growth in STZ-induced diabetes in mice.Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse.Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma.Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma.IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis.Diverse Expression of IL-32 in Diffuse and Intestinal Types of Gastric CancerInterleukin-33/ST2: A new signaling pathway in immunity and immunopathologyDeletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activityInterleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinomaClinical significance of Cyclin D1, FGF3 and p21 protein expression in laryngeal squamous cell carcinomaST2 deletion increases inflammatory bone destruction in experimentally induced periapical lesions in miceIL-33 receptor (ST2) deficiency downregulates myeloid precursors, inflammatory NK and dendritic cells in early phase of sepsisDeletion of Galectin-3 attenuates acute pancreatitis in mice by affecting activation of innate inflammatory cells
P50
Q27011437-8940745F-4019-4BF9-9AA9-905BF5135A84Q33604689-A0FD14E5-7823-4567-B0B5-6918DA503054Q33962407-7B94CBB7-2C17-4778-A85C-AC691E7FABEEQ35720450-0944FACD-2B0C-4AE7-9517-D48EB9DBBED3Q37101727-AC40EE9E-F78D-419B-8FE0-4AD3EACBA5BEQ37109698-BF7D14CE-E549-446F-B782-8CE8FAD78E22Q37990785-6F1479C3-3F69-4E47-BB61-63E4E7E7E41BQ38773856-65DC871A-30D2-46A7-99C8-220D22357D44Q39084378-E5E4B75B-D2ED-4D5A-8A4F-2CA131D0C060Q40944709-5F3A8DFC-8A74-4092-A4DD-55B0521EC398Q41090928-92D55490-3ABA-4E89-A4A1-084BFC469CE3Q42204336-F12D2F33-B563-404D-B886-8232B0C86435Q42624178-99D7B33C-5162-4F83-B485-4DAC976EF13BQ43299666-F90BAE06-9CF7-4D00-A8A2-A980585C39E3Q46033310-B1D826E7-0F44-424C-8189-F7ACC9C6D826Q46242249-0D49C923-0013-4644-9640-8AD1B8F294E3Q47155489-63DC3943-ABFB-4D43-8922-F56ED412F073Q49124447-8F3EE736-4D7B-4562-BFDF-9BDC6AC712F8Q49832605-85B74519-F93D-48B5-8D00-FE3C49FE3CCEQ50743494-AC35F087-8CD0-48B4-986C-2C96326992E3Q53296607-A0A74B25-B8B1-49E6-AC2F-E8E337F4B1FEQ55259032-B2182852-3421-4BC1-90A0-E3CC6F84C67BQ55514878-F0C33AD5-EE12-4BEE-B4FD-E1CC53D1F857Q58584387-48D3D1BA-BB6A-49DD-92E9-6181800223BCQ61903467-4A59847F-712F-4BAB-9D3D-859AAEC196C0Q61903522-C2B3D676-8048-436D-8EA1-0B471B86D56BQ61903591-6D0A4457-1D39-4353-90FC-91CE1B2DC189Q86392632-27E2AAC1-0171-4626-8F13-60DC8E4C5918Q86547233-1B054D47-EA44-4F90-AF42-CF9F0C6A4F67Q90003013-40F5E0D5-BE32-475A-A814-0EB5631638C2Q92500903-08CB8378-F442-4DF1-9F9E-E23601B08B97
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ivan P Jovanovic
@ast
Ivan P Jovanovic
@en
Ivan P Jovanovic
@es
Ivan P Jovanovic
@nl
type
label
Ivan P Jovanovic
@ast
Ivan P Jovanovic
@en
Ivan P Jovanovic
@es
Ivan P Jovanovic
@nl
prefLabel
Ivan P Jovanovic
@ast
Ivan P Jovanovic
@en
Ivan P Jovanovic
@es
Ivan P Jovanovic
@nl
P106
P21
P31
P496
0000-0002-1169-2378